Dalpiciclib hydrochloride

盐酸达匹昔利布

Dalpiciclib hydrochloride

D659080-5mg

5mg

≥99%

2-8°C储存,干燥

冰袋运输

Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC 50 values of 12.4 nM and 9.9 nM, respectively. Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esophageal s Appearance:Solid IC50& Target:CDK6 9.9 nM (IC 50 ) CDK4 12.4 nM (IC 50 ) In Vitro:Dalpiciclib hydrochloride (0-4 μM, 72 h) inhibits cell proliferation in a dose-dependent manner. Dalpiciclib hydrochloride (0-10 μM, 6 d) inhibits the proliferation of retinoblastoma-positive tumor cell lines. MCE has not independently confirmed In Vivo:Dalpiciclib hydrochloride (oral gavage; 150mg/kg; once weekly; 3 weeks) shows antitumor activity against ESCC xenografts. Dalpiciclib hydrochloride combined with Paclitaxel (PTX) or Cisplatin (CDDP) offer synergistic inhibitory effects in ESCC xenog Biological Activity:Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC 50 values of 12.4u2009nM and 9.9u2009nM, respectively . Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esop

C25H31ClN6O2

483.01 g/mol

O=C1C(C(C)=O)=C(C)C2=C(N1C3CCCC3)N=C(NC4=NC=C(C5CCNCC5)C=C4)N=C2.[H]Cl

DMSO : 5 mg/mL (10.35 mM; ultrasonic and warming and heat to 60°C)

包含CDK，MAPK，GSK3，CLK家族